Imaplix

Apremilast, the active ingredient in Imaplix, is a phosphodiesterase 4 (PDE4) inhibitor presented as a tablet (strength not specified) for oral use. It is employed to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adult patients. It is approved for use in the European Union and is available only by prescription, reflecting its status as a targeted immunomodulatory therapy.

GNH USA supplies Imaplix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across multiple markets.

Apremilast is indicated for inflammatory skin and joint disorders within the psoriasis disease spectrum.

- Plaque psoriasis: reduces the extent and severity of skin lesions, improving patient‑reported outcomes. - Psoriatic arthritis: alleviates joint pain, swelling and stiffness, helping maintain functional ability. - Moderate to severe psoriasis in adults: provides an oral alternative when biologic therapy is unsuitable.

Apremilast may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: loose stools often occurring early in treatment. - Nausea: mild to moderate feeling of queasiness. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Weight loss: gradual decrease in body weight.

Serious or Rare Side Effects: - Depression or suicidal thoughts: new or worsening mood disturbances. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: abdominal pain with elevated enzymes. - Hepatic injury: significant elevation of liver enzymes. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin detachment.

Before initiating Apremilast therapy, clinicians should consider several precautionary measures to ensure patient safety.

- Baseline liver assessment: obtain hepatic function tests and monitor periodically. - Mental health evaluation: screen for depression and suicidal ideation prior to and during treatment. - Renal function review: adjust dosing in patients with severe renal impairment. - Concomitant medication review: avoid use with strong CYP3A4 inducers or inhibitors without supervision. - Hypersensitivity: discontinue if signs of allergic reaction develop. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Apremilast can interact with other medicines, affecting its plasma concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce apremilast exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase apremilast levels and risk of toxicity. - Methotrexate: combined use may heighten hepatic toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR values for potential anticoagulant effect changes. - Antacids containing aluminum or magnesium: may affect apremilast absorption; separate dosing by at least 2 hours. - Ritonavir: may require dose adjustment due to moderate CYP3A4 inhibition.